Navigation Links
Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine

WALTHAM, Mass., Feb. 7 /PRNewswire/ -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today that its co-founder and CEO Mitchell P. Fink M.D. was presented with the Distinguished Investigator Award from the American College of Critical Care Medicine during the 37th Critical Care Congress of the Society of Critical Care Medicine held February 2-6 in Honolulu, Hawaii.

The prestigious recognition was awarded to Dr. Fink for his pioneering research related to the pathogenesis and treatment of sepsis, a serious medical condition characterized by widespread inflammation, due to infection.

Dr. Fink was the Founding Chairman of the Department of Critical Care Medicine at the University of Pittsburgh, the first such department at a medical school in the United States. Dr Fink also held other University appointments including Professor of Pharmacology, the Watson Professor of Surgery, and Associate Vice-chancellor for Translational Research. Dr. Fink's academic research program was continuously funded by the National Institutes of Health for more than 20 years.

The Society of Critical Care Medicine, which bestowed the honor to Dr. Fink, is the leading professional organization dedicated to ensuring excellence and consistency in the practice of critical care medicine. With more than 13,000 members worldwide, the Society is the only professional organization devoted exclusively to the advancement of multi-professional intensive care through excellence in patient care, professional education, public education, research and advocacy.

Dr. Fink is an author or co-author of more than 250 peer-reviewed scientific publications, has edited or co-edited 13 textbooks and is currently an Associate Editor for two highly regarded scientific journals: the Journal of Pharmacology and Experimental Therapeutics and the Journal of Leukocyte Biology.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Waltham, Massachusetts. Logical Therapeutics is developing drugs to treat a variety of medical conditions that are caused by or are associated with excessive inflammation, including various forms of arthritis, obesity and type 2 diabetes mellitus. For more information on Logical Therapeutics, visit the company's website at or by email at

SOURCE Logical Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
2. Neurobiological Technologies Sets Date for Second Quarter Financial Results
3. Montana State University lab gives early warnings about biological invaders
4. Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Womens Biological Clock
5. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. The Tauri Group LLC Awarded U.S. Department of Homeland Security Chemical and Biological Early Detection Systems Program Office Support Contract
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
10. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
11. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
Post Your Comments:
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
Breaking Biology News(10 mins):